Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868836 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4596956 | 0.92 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4595342 | 0.92 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4597235 | 0.92 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7207955 | 0.92 | MEN1 (0.65) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL5940404 | 0.90 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL6800013 | 0.89 | TSHR (0.62) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3909091 | 0.87 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL6130666 | 0.87 | MEN1 (0.43) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL10506890 | 0.87 | TSHR (0.59) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050064468-A1 | concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports | IBC ADVANCED TECHNOLOGIES, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1453602-A4 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECH INC (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1453602-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6774082-B2 | COMPOSITION FOR USE IN THE SEPARATION OF PREFERENTIAL BIOPOLYMERS FROM SAMPLE | IBC ADVANCED TECHNOLOGIES, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20030050458-A1 | Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences | IBC ADVANCED TECHNOLOGIES, INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002092766-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050458-A1 | Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences | NUDT1, ATIC, PNP | MEN1 3288/4885KMT2A 967/4885TSHR 2759/4885 |
| US-20050064468-A1 | concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports | NUDT1, PCNA, NSUN2 | MEN1 2474/4885KMT2A 571/4885TSHR 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.